The estimated Net Worth of James A Johnson is at least 2.45 千$ dollars as of 29 March 2023. James Johnson owns over 5,000 units of Athira Pharma stock worth over 2,450$ and over the last 11 years James sold ATHA stock worth over 0$.
James has made over 2 trades of the Athira Pharma stock since 2016, according to the Form 4 filled with the SEC. Most recently James bought 5,000 units of ATHA stock worth 12,000$ on 29 March 2023.
The largest trade James's ever made was exercising 10,000 units of Athira Pharma stock on 10 November 2016 worth over 51,200$. On average, James trades about 750 units every 116 days since 2014. As of 29 March 2023 James still owns at least 5,000 units of Athira Pharma stock.
You can see the complete history of James Johnson stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Over the last 4 years, insiders at Athira Pharma have traded over 100,296$ worth of Athira Pharma stock and bought 5,411,219 units worth 62,123,025$ . The most active insiders traders include Advisors Llcperceptive Life...、Investments, Lpwong Roderic...、Joseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of 62,547$. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth 725$.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma executives and other stock owners filed with the SEC include: